bioRxivBioengineeringPreprint
Designed nanofiber immunogens prime antibody responsesto diverse conformations of the HIV-1 fusion peptide
Chelsea N. FriesiD, Jui-Lin Chen, Nicole L. VotawiD, Benjamin James Cossette, Emily F. RoeiD, Maria L. DennisiD, Elizabeth J. CurvinoiD, Luqman A. Issah, K. Lázár, Shamitha ShettyiD, Rachel Katz, Corrine A. NiefiD, Sallie R. PermariD, Koen K. A. Van RompayiD, Genevieve G. FoudaiD, Joel H. CollieriD
Abstract
Focusing antibody responses towards known neutralizing epitopes is a major strategy for protective immunization. Targeting flexible antigenic regions represents a unique challenge because functional antibodies must be able to bind the epitope of interest in multiple conformations. The fusion peptide (FP) of HIV-1 is a flexible peptide critical to viral entry of host cells for which broadly neutralizing antibodies have been identified. Because elicitation of potent, functional antibodies toward this epitope remains an unmet challenge in HIV-1 vaccination, we introduce a designed immunogen platform capable of raising anti-FP-antibodies with increased conformational tolerance relative to a traditional carrier protein. Antibodies induced by these immunogens bind heterologous FP sequences when elicited in mice and infant non-human primates. This platform shows promise for preclinical development to prime antibody responses toward FP of the HIV-1 envelope and can likely be translated to peptide immunofocusing for other viral pathogens.
- organism: mouse
- organism: non-human primate
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1
K. Xu, P. Acharya, … McDermott·bioRxiv·Apr 23, 2018
- Virus-Like Particle Based-Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide
A. T. Mogus, L. Liu, … B. Chackerian·bioRxiv·Sep 25, 2020
- Novel HIV-1 fusion peptide immunogens using glycan-engineered alphavirus-like particles
Seo-Ho Oh, Dedeepya R. Gudipati, … Rui Kong·npj VaccinesPeer-reviewed·Nov 14, 2025
- Vaccine-elicited and naturally elicited antibodies differ in their recognition of the HIV-1 fusion peptide
Mateo Reveiz, Kai Y. Xu, … Reda Rawi·Frontiers in ImmunologyPeer-reviewed·Nov 14, 2024
- Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV
A. S. Dingens, P. Acharya, … J. D. Bloom·bioRxiv·Apr 24, 2018
- Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope
M. E. Abernathy, H. B. Gristick, … P. J. Bjorkman·bioRxiv·Mar 17, 2021